Last month, Murali Neelakantan joined Glenmark Pharmaceuticals as its president and global general counsel. Neelakantan leads the legal and compliance functions for the organization globally.
Neelakantan is qualified to practise both in India and England and Wales. He has over 20 years of international experience in advising companies across a variety of sectors. He was the global general counsel of Indian generic drugs manufacturer Cipla before resigning in February 2015 to pursue policy work and teaching opportunities. Prior to this, he was a senior partner at Khaitan & Co, an equity partner and head of the India practice at Ashurst, and a partner and co-chair of the Asia working group at Arnold & Porter (now Arnold & Porter Kaye Scholer). In the early years of his career, he worked with Simmons & Simmons and Nishith Desai Associates.
During the past two years Neelakantan taught courses at the National University of Juridical Sciences in Kolkata and was involved in running a pharmaceutical policy programme at Ashoka University in Delhi. When he resigned from Cipla, he told India Business Law Journal that more work was needed to connect academics with legal practitioners and industry professionals to ensure “teaching in a multidisciplinary way”.